AUG 7, 2026 · PHASE 3 TRIAL
Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC
ClinicalTrials.gov
This is a Phase 3 trial registration with no posted results; the study is actively recruiting and has not yet generated outcome data.
Reported
Planned enrollment1520
Study phasePHASE 3
Primary outcome measure5-year invasive disease-free survival (iDFS)